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Abstract
Background: Factors affecting immune responses to influenza vaccines have not been studied systematically. We
hypothesized that T-cell and antibody responses to the vaccines are functions of pre-existing host immunity against
influenza antigens.
Methodology/Principal Findings: During the 2004 and 2005 influenza seasons, we have collected data on cellular and
humoral immune reactivity to influenza virus in blood samples collected before and after immunization with inactivated or
live attenuated influenza vaccines in healthy children and adults. We first used cross-validated lasso regression on the 2004
dataset to identify a group of candidate baseline correlates with T-cell and antibody responses to vaccines, defined as fold-
increase in influenza-specific T-cells and serum HAI titer after vaccination. The following baseline parameters were
examined: percentages of influenza-reactive IFN-c
+ cells in T and NK cell subsets, percentages of influenza-specific memory
B-cells, HAI titer, age, and type of vaccine. The candidate baseline correlates were then tested with the independent 2005
dataset. Baseline percentage of influenza-specific IFN-c
+ CD4 T-cells was identified as a significant correlate of CD4 and CD8
T-cell responses, with lower baseline levels associated with larger T-cell responses. Baseline HAI titer and vaccine type were
identified as significant correlates for HAI response, with lower baseline levels and the inactivated vaccine associated with
larger HAI responses. Previously we reported that baseline levels of CD56
dim NK reactivity against influenza virus inversely
correlated with the immediate T-cell response to vaccination, and that NK reactivity induced by influenza virus depended on
IL-2 produced by influenza-specific memory T-cells. Taken together these results suggest a novel mechanism for the
homeostasis of virus-specific T-cells, which involves interaction between memory helper T-cells, CD56
dim NK and DC.
Significance: These results demonstrate that assessment of baseline biomarkers may predict immunologic outcome of
influenza vaccination and may reveal some of the mechanisms responsible for variable immune responses following
vaccination and natural infection.
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Introduction
Influenza viruses are major respiratory tract pathogens for
people of all ages, especially the elderly and very young [1].
Currently two types of influenza vaccines are available: the
inactivated trivalent influenza vaccine (TIV), given intramuscu-
larly [2], and the live attenuated influenza vaccine (LAIV),
administered intranasally [3]. TIV is approved for use in people
ages 6 months or older, LAIV is approved for use in persons 2–49
years of age. Both vaccines are considered safe and effective for the
designated age groups, although a recent study found that in
healthy children aged 6 months–4 years, LAIV had significantly
better efficacy than TIV for both antigenically well-matched and
drifted strains [4]. In contrast, it was reported that in healthy
adults aged 18–49, TIV and LAIV were similarly effective against
drifted type A (H3N2) viruses, but that TIV was superior against
type B infections [5].
Most adults and older children have pre-existing immunity
against influenza viruses due to prior infection or vaccination
[6,7,8]. However, antigenic drift of influenza virus, which is caused
by accumulation of point mutations in viral genes encoding the
two surface proteins, hemagglutinin and neuraminidase, occurs
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infected by or vaccinated against previously circulated influenza
viruses may be susceptible to a new virus strain. Therefore, the
influenza vaccine is reformulated each year based on international
surveillance that predicts which virus strains will circulate in the
coming year.
Antibodies to hemagglutinin and neuraminidase have been
associated with protection from disease and/or viral replication
after natural influenza infection or vaccination in adults and
children [11,12,13,14,15,16,17]. Based primarily on studies in
animal models, T-cell responses are also thought to play an
important role in clearing influenza virus infection
[18,19,20,21,22,23,24]. Much less is known regarding the role of
innate immune responses during influenza infection or following
vaccination. Most of the previous immunological studies on
vaccination focused on single or few adaptive immune parameters,
such as the titer of virus-specific antibody or number of virus-
specific T-cells. However, the complex interplay of factors
affecting these immune responses, which are critical for under-
standing the efficacy of vaccination, have not been investigated
systematically, especially for the cellular immune responses.
During the 2004 and 2005 influenza seasons, we carried out a
comprehensive study to investigate humoral and cellular immune
responses in children and adults immunized with either LAIV or
TIV. The following parameters of the adaptive and innate
immune compartments were measured with blood samples
collected before and after vaccination: the percentage and
phenotype of influenza-specific T-cells, the percentage of influen-
za-reactive IFN-c–producing CD56
bright and CD56
dim NK cells,
the percentage of influenza virus-specific IgG and IgA memory B-
cells and antibody-secreting effector B-cells, and the titer of serum
hemagglutination inhibition (HAI) antibodies. Some of these
results have been reported in our previous publications that
focused on the comparison of these responses between children
and adults and between TIV and LAIV recipients [7,8,25].
An immune response is the outcome of orchestrated interactions
between foreign antigen and host immune cells, initiated upon the
entry of a pathogen or vaccine into the body. These interactions
differ among people based in part on different levels of immune
memory resulting from previous related infection or immunization.
The immune memory, including virus-specific antibody and
memory B-cells and T-cells, can be quantitatively measured with
different assays at the time of vaccination. In addition, the immune
responses may also be influenced by host factors such as age that
affects function of immune cells, type of vaccine that affects
pathways of antigen presentation, and host genetic characteristics.
Inthecurrentstudy,weconsideredimmune response to vaccination
as a function of multiple demographic and immune variables, and
explored the relationship between the baseline immune parameters
and immune responses to vaccination, defined as changes of the
parameters after vaccination. We focused on three of our measured
parameters that are believed to represent critical characteristics of
protective immunity: HAI titer and the frequency of influenza-
specific CD4 and CD8 T-cells in the peripheral blood.
A distinctfeature ofthis studyis thatanalysismade effective useof
two separate and independent datasets from the same population.
The first dataset was collected during the 2004 influenza season.
This sample was used to identify a list of candidate baseline
correlates with each immune response. The second dataset was
collected during the 2005 influenza season, in which a different
influenza A/H3N2 strain was used in both the vaccines and the
assays. Thisseconddataset allowedus toassesswhichoftheputative
correlations were sufficiently robust to sampling error to remain
statistically detectable in a new, independent sample.
Methods
Human participants and vaccination protocols
Prior to the fall 2004 and 2005 influenza seasons, children 5–9
years of age and adults 22–49 years of age were enrolled into a
multi-project influenza vaccine study. The study protocol was
approved by the institutional review board at Stanford University.
Written informed consent was obtained from participants or their
parents while assent was obtained from children 7 years and older.
For the current analysis, we excluded all 2004 participants from
the 2005 dataset, so that the 2004 and 2005 datasets had no
participants in common and thus represent statistically indepen-
dent samplings. Demographic information on the included study
participants are summarized in Table 1. Participants were
immunized with either TIV (Fluzone, Sanofi Pasteur) or LAIV
(FluMist, MedImmune) following current guidelines for influenza
vaccination. All the adult participants in the 2004 study were
participants of a study in the previous fall 2003 influenza season, in
which they were randomized in a 1:1 ratio to receive either TIV or
LAIV. For the 2004 study, these participants were immunized
with the same type of vaccine as they received in the previous year.
All adult participants in the 2005 study were randomized in a 1:1
ratio to receive either TIV or LAIV. The 5–9 year old children
were randomized in a 1:1 ratio to receive either TIV or LAIV in
both years. For those influenza vaccine-naı ¨ve children, a second
dose of the same vaccine was given at approximately 28 days (for
TIV) or 42 days (for LAIV) after the first dose according to
recommendations. The 2004 TIV and LAIV vaccines both
contained A/New Caledonia/20/99 (H1N1) and A/Wyoming/
03/2003 (H3N2) strains. The third strain was B/Jiangsu/10/2003
in TIV and B/Jilin/20/2003 in LAIV. The 2005, TIV and LAIV
vaccines both contained the A/New Caledonia/20/99 (H1N1)
and B/Jiangsu/10/2003 (B) strains. The third strain was A/
California/7/2004 (H3N2) in LAIV and A/NewYork/55/2004
(H3N2, an A/California/7/2004-like strain) in TIV.
Assays for immune parameters
Assay results from blood samples collected on day 0 (pre-
vaccination) and day 28–42 (post-vaccination) were used in this
analysis. The percentages of IFN-c–producing CD4 and CD8 T-
cells and CD56
bright and CD56
dim NK cells were measured with
an IFN-c flow cytometric assay after incubating PBMC with a live
influenza A (fluA) H3N2 strain for 17 hours [7]. The percentage of
influenza-specific memory IgA and IgG B-cells were measured
with a two-color ELISPOT assay after culturing PBMC with
polyclonal stimulation for 5 days [8]. The titer of serum HAI
antibodies against fluA H3N2 was measured as previously
described [8]. The PBMC samples collected during the 2004 or
2005 season were tested with either TIV (for ELISPOT), or the
fluA H3N2 strain similar to the vaccine component of the same
season (for IFN-c flow cytometry and HAI assays), respectively.
For the IFN-c and HAI assays, we focused on results with H3N2
subtype virus because influenza A/H3N2 has, in recent years,
generally been a more virulent strain compared to other strains
and has exhibited more antigenic variation from season to season.
In addition, the H3N2 component differed between the 2004 and
2005 vaccines, making any consistent finding between our two
samples indicative of a more robust result.
Identification of baseline correlates with immune
responses with the 2004 dataset
The 2004 dataset was used to identify candidate baseline
correlates of three immune responses specific for the fluA H3N2
strain: CD4 T-cell response, CD8 T-cell response, and HAI
T-Cell Responses to Vaccines
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from baseline (day 0) in percentage of fluA-specific IFN-c
+ CD4
and CD8 T-cells and fold-change from baseline in HAI titer of the
post-vaccination blood samples. One vaccine variable (TIV vs.
LAIV), two host age variable (less than 10 years vs. at least 18
years, age in years) and the following 7 baseline immune variables
were evaluated for their correlations with each of the three
immune responses: percentage of IFN-c
+ CD4 T-cells, percentage
of IFN-c
+ CD8 T-cells, percentage of IFN-c
+ CD56
bright NK cells,
percentage of IFN-c
+ CD56
dim NK cells, percentage of influenza-
specific IgA memory B-cells, percentage of influenza-specific IgG
memory B-cells, and HAI titer. The percentage of IFN-c
+ cells was
logarithm-base-10 transformed, while HAI titers were logarithm-
base-2 transformed, for all analyses. Vaccine type and age group
were coded as indicator variables [26] (pp. 455–457) for analysis.
We chose to include both age in years and age group as possible
baseline correlates because, a priori, we did not know to what
extent variation in ages within adults and within children may
contribute to prediction beyond that by age groups alone (see
results).
In the 2004 sample, we employed lasso regression [27] with five-
fold cross-validation [28](p. 216) for the specific purpose of
empirically identifying a list of candidate baseline correlates with
immune response (and not for obtaining estimates of regression
coefficients). Lasso regression generates a sequence (path) along
which regression variables are removed one by one. For five-fold
cross-validation we randomly split the 2004 data set into five parts
of approximately equal quantities of participants. A lasso
regression model was fit to the data on the last four parts
combined (training) and then the data from the first part were
applied to that fitted model and error was measured via the
predicted residual sum of squares (PRESS) statistic (validation).
The process was then repeated four more times, allowing each
part (2, 3, 4, 5) to serve separately as the validation data for a
training on the other four parts combined. When the sample size is
modest, such as in this dataset of 71 participants, the cross-
validation component is small (71/5<14 participants), making
cross-validation results less stable. To enhance stability, we
repeated cross-validation 150 times, each time using a separate
random splitting of the 2004 data set into five parts of
approximately equal quantities of participants. This yielded 150
removal sequences of candidate baseline correlates. We identified
as most robust that specific removal sequence which occurred
most frequently among these 150. From this specific sequence, the
optimal subset retained for independent testing with the 2005 data
was that combination of candidate baseline correlates which had
the smallest cross-validated PRESS statistic. Within this optimal
subset, we defined strength of candidacy according to order of
removal had variable selection been allowed to proceed below the
optimum. This allowed us to address any co-linearity among
candidates by prioritizing order of hypothesis testing from
strongest to weakest candidates. The entire variable-selection
analysis was performed separately for each of the three immune
responses.
Validation of baseline correlates for immune responses
with the 2005 dataset
Using the independent 2005 sample, we performed ordinary
multiple regression of each immune response on its subset of
candidate baseline correlates identified from 2004. Using Type I
sums of squares [29], each candidate baseline correlate was tested
for association with immune response after having adjusted for all
other baseline correlates of stronger candidacy in the subset. An
association was declared statistically significant for attained
significance levels of p,0.05.
Results
To identify candidate baseline correlates for CD4 T-cell, CD8
T-cell and antibody responses to vaccination, we used the 2004
dataset with 71 participants. For a few participants, data were
missing on either baseline (day 0) or day 28: 3 missing observations
for baseline IgA memory B-cells, one for baseline HAI titer, and
one each for day 28 HAI titer, CD4 and CD8 T-cells. Lasso
regression analysis of this dataset identified one candidate baseline
correlate for fold-change in percentage of fluA-specific CD4 T-
cells, which was the baseline percentage of fluA-specific CD4 T-
cells. Two candidate baseline correlates were identified for fold-
change in percentage of flu-specific CD8 T-cells. These were adult
age group (weakest candidate) and baseline percentage of flu-
specific CD4 T-cells (strongest candidate). Three candidate
baseline correlates were identified for fold-change in HAI titer.
In order of increasing strength of candidacy these were vaccine
type, age in years and baseline HAI titer.
Next we used regression analysis to test each of the candidate
baseline correlates, using the independent 2005 dataset that
includes a total of 56 adult and child participants. HAI data were
missing for one child participant. Results are provided in Table 2.
Baseline percentage of fluA-specific CD4 was associated with fold-
change in percentage of flu-specific CD4 T-cells (p=0.0003). The
negative estimate of the regression coefficient indicates that the
relationship between this baseline correlate and immune response
Table 1. Demographic information of the study population.
Study year Age group Vaccine group N (female/male
1) Age
1 mean6SD
2004 Child 5–9 yr LAIV 13 (6/7) 6.961.4
TIV 15 (3/12) 7.161.0
Adult 22–49 yr LAIV 19 (11/8) 29.765.8
TIV 18 (10/8) 32.668.2
2005 Child 5–9 yr LAIV 8 (3/5) 6.361.0
TIV 12 (5/7) 6.861.8
Adult 22–49 yr LAIV 20 (15/5) 31.568.0
TIV 16 (13/3) 31.169.4
1We did not detect a difference in gender composition (logistic regression p=0.07) or in natural-logarithm transformed age (linear regression p=0.42) between the
2004 and 2005 populations.
doi:10.1371/journal.pone.0002574.t001
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declined with increasing percentage at baseline (Fig. 1A). Fold-
change in percentage of fluA-specific CD8 T-cells was associated
with baseline percentage of fluA-specific CD4 T-cells (p=0.0397)
but not with age group in the 2005 data (p=0.3684, Fig. 1B). Fold-
change in HAI was associated with baseline HAI titer (p,0.0001)
and with vaccine type (p=0.0098) but not with age in years
(p=0.5864). The estimated regression coefficient for vaccine type
(LAIV) is negative, indicating that fold-change from baseline in
HAI titer is smaller after LAIV than after TIV vaccination
(Fig. 1C).
Six separate hypothesis tests were performed on the 2005
sample, across which the probability of a Type I error compounds.
If we take a conservative approach and adjust for multiple testing
[30], three of the associations between candidate baseline
correlates and immune responses remain statistically significant:
baseline percentage of fluA-specific CD4 T-cells with fold-change
in percentage of fluA-specific CD4 T-cells, baseline HAI titer with
fold-change in HAI and vaccine type with fold-change in HAI
titer. Of note, these three associations remain statistically
detectable after two checks on their robustness-testing in a new
independent sample and correction for multiple testing.
Beyond identifying where association may exist, we can quantify
strength of association with estimates of correlation parameters.
Table 2 also provides estimates of the strength of association
between each individual candidate baseline correlate and its
immune response using estimates of Pearson partial correlation rp
coefficients [31](pp. 426–428). Each partial correlation coefficient
is adjusted for all stronger candidate baseline correlates with that
immune response (Table 2). For example, the association between
fold-change in HAI titer and vaccine type is adjusted for baseline
HAI titer and age in years. The parameter rp can range in value
from 21 to 1, with 0 representing no linear correlation. Estimated
partial correlations for our data range from small (20.12) to
modest (20.49).
We can also estimate the strength of association between each
immune response and its corresponding full set of candidate
baseline correlates identified from the 2004 sample (one correlate
for CD4 T-cell, two for CD8 T-cell and three for HAI responses)
using estimates of the coefficient of multiple correlation R
Figure 1. Scatter plot of immune responses versus identified baseline correlates for the 2005 sample. Immune responses are defined as
the post-vaccination fold-change of each immune parameter from its baseline level. Each open or closed circle on the plot is an observation from a
single participant. Lines indicate fit of the multiple regression model to the data. A. CD4 T-cell response versus baseline percentage of fluA-specific
IFN-c
+ CD4 T-cells. B. CD8 T-cell response versus baseline percentage of fluA-specific IFN-c
+ CD4 T-cells. C. HAI response versus baseline HAI titer.
doi:10.1371/journal.pone.0002574.g001
Table 2. Estimated regression coefficients from the 2005 sample.
Immune response
Candidate Baseline
Correlate
Estimated
Regression
Coefficient p value
Partial
Correlation
Coefficient rp
Estimated Coefficient
of Multiple
Correlation R
Estimated Coefficient
of Multiple
Determination R
2
CD4 T-cell response % CD4 -0.41 0.0003 20.47 0.47 0.22
CD8 T-cell response % CD4 -0.23 0.0397 20.28 0.3 0.09
Adult Group 20.18 0.3684 20.12
HAI response Log2 HAI titer 20.43 0.0002 20.47 0.62 0.39
Age (years) 20.009 0.5668 20.13
LAIV Vaccine Type 21.39 0.0007 20.45
Within each immune response, candidate baseline correlates are ordered from strongest (top row) to weakest (bottom row) candidacy based on the 2004 lasso
regression. Reported p-values are for the null hypothesis that the regression coefficient is equal to zero. Partial correlation coefficients are simple correlations
[31](p. 426) for the first row of each immune response, because these are not adjusted for any other candidate correlates.
doi:10.1371/journal.pone.0002574.t002
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association to 1 for perfect association. We observed R values of
0.3 to 0.57 (Table 2). The square of R is the coefficient of multiple
determination. R
2 can be interpreted as the proportion of the
variance in the immune response explained by its candidate
baseline correlates [26](pp. 230–231). These values are 0.09 for
CD8 T-cell response, 0.22 for CD4 T-cell response, and 0.33 for
HAI response for the full set of correlates identified in the 2004
sample. That is, up to 9% to 33% of the immune responses can be
explained by the combined baseline correlates that we identified
from 2004. If only those variables of statistically significant
association with immune response are included (as assessed with
the 2005 data), these multiple correlation and determination
estimates would be lower.
Discussion
Our working hypothesis for this study is that immune responses
to vaccine antigens are a function of overall immunity against the
antigen at the time of vaccination, as well as a function of the host
and vaccine variables that influence activity of immune cells. To
test this hypothesis, we searched among a total of seven influenza-
specific baseline immune variables related to either the adaptive or
innate immune system, two age-related host variables and one
vaccine variable for baseline correlates of T-cell and antibody
responses to influenza vaccination. We identified baseline levels of
fluA-specific memory CD4 T-cells as a significant negative
baseline correlate with CD4 and CD8 T-cell responses, and
baseline levels of HAI titer and type of vaccine (LAIV) as
significant negative correlates with antibody response.
Among the immune variables we examined, CD4 helper T-cells
are required for B-cell responses, which are related to antibody
responses, and for cytotoxic CD8 T-cell responses. Pre-existing
memory B-cells can be activated and develop into high affinity
antibody-secreting effector B-cells upon encountering related
antigens. In addition, activated B-cells may secrete cytokines and
serve as antigen-presenting cells (APC) for T-cell responses [32].
The relationship between the levels of pre-existing memory T-cells
and B-cells in the periphery and the subsequent B- and T-cell
responses to a new influenza infection or immunization is not
known. NK cells, as a member of the innate immune system,
provide a first line of defense against viral infection, which may
affect the subsequent adaptive T-cell responses [33,34,35].
However, most previous immunological studies of influenza
vaccines have focused on adaptive immunity, i.e. antibody and T-
cell responses, and rarely on innate immunity. In limited influenza
vaccine studies, an enhanced NK cytotoxicity has been seen
following vaccination in some studies [36,37] but not in others [38].
In addition to the immune variables, we chose age in years and
age group (child vs. adult) as host factors, and type of vaccine as
another factor to be considered, based on our previous findings on
the different cellular immune responses to influenza vaccination
between the different age and vaccine groups [7,8,25,39]. LAIV
and TIV are administered through different routes and elicit CD8
T-cell responses through different antigen presentation pathways.
LAIV is administered to the nasal mucosal surface. Similar to
natural infection with wild-type virus, LAIV is presumed to
undergo replication at the site of immunization and infects APC.
This viral replication may be limited to variable degrees based on
the strength of innate and adaptive immunity, which are likely to
affect the magnitude of subsequent adaptive immune response to
LAIV. In contrast, TIV is administered by intramuscular injection
and induces systemic immune responses. Hence the variable
microenviroment in T-cell activation sites and different pathways
of antigen presentation associated with these two vaccines may
result in different immune responses to the two vaccines.
The2004 and2005 datasetshave noparticipantsincommonand
thus represent statistically independent samplings. This allowed us
to use one dataset to identify candidate baseline correlates with
immune response and the other to independently verify which of
these candidate baseline correlates are statistically associated with
immune response. Testing for association in an independent dataset
is statistically advantageous. Use of an independent sample
strengthens findings by identifying associations that are less affected
by the idiosyncrasies of the sample used for initially selecting
candidate baseline correlates. In particular, bias is avoided in
estimates of p-values and regression coefficients [40] that arise when
conductinghypothesis testson thosesame data that suggested which
hypotheses to test (‘‘data snooping,’’ [26] pp. 724–725).
Based solely on serological data, previous studies in our group
and others have shown that lower baseline levels of influenza-
specific antibody and vaccination with TIV rather than LAIV
were associated with greater antibody response after vaccination
[8,41,42]. These same factors have emerged out of the 10 variables
that we examined as the only baseline correlates with antibody
response to influenza vaccination, providing further evidence of
the robustness of the findings reported here.
Our analysis also identified baseline levels of fluA-specific IFN-c
+
CD4 T-cells as a significant baseline correlate for both CD4 and
CD8 T-cell responses to influenza vaccination with an inverse
correlation, even though the association is only modest in strength.
What is the possible underlying mechanism for this association?
Most adults and older children have been exposed to previous
influenza infection or vaccination [6,7,8], and therefore have
certain levels of influenza-specific memory T-cells in peripheral
blood [7]. Previously we reported that when PBMC were incubated
with fluA, the IFN-c response of NK cells depended on the T-cell
population, and the effects of T-cells could be replaced by
recombinant IL-2 [43]. IL-2 is a cytokine transiently produced by
activated T-cells, especially CD4 helper T-cells [44]. These findings
indicate that IL-2 produced by fluA-specific memory CD4 T-cells is
involved in the response of NK cells to fluA.
DC play a central role in both innate and adaptive immunity.
DC process and present viral antigens to specific T-cells, resulting
in activation and amplification of virus-specific T-cells, which
constitute the primary or secondary T-cell responses to viral
infection or vaccination. Depending on their maturity and
functional status, DC can also tolerize T-cells, rendering them
anergic to cognate antigens [45]. Studies using in vitro cultured
NK cells and DC have shown that NK-DC interaction may result
in their reciprocal activation, as well as inhibition of DC by NK, in
different circumstances [34,35,46,47,48]. At low NK/DC ratios
DC responses were amplified dramatically, while at high NK/DC
ratios DC responses were inhibited completely. The inhibition of
DC functions by NK cells was mediated by the potent DC killing
activity of the autologous NKs cells [47], which is most likely
mediated by the CD56
dim NK cell subset that expresses high levels
of perforin [49]. Therefore, depending on the magnitude of
CD56
dim NK activity during the early stage of infection, the NK
cells could either enhance or suppress subsequent adaptive T-cell
responses by activating or inhibiting DC. Of note, CD56
dim NK
cells stimulated by tumor cells were both cytolytic and IFNc-
producing [50], suggesting an association between these two
effector functions of the CD56
dim NK population. Of special
interest, previously we showed that the immediate T-cell responses
after vaccination, defined as the fold-change in percentage of IFN-
c
+ CD4 and CD8 T-cells by day 10 after vaccination, was
inversely correlated with baseline levels of fluA-reactive IFN-c
+ T-
T-Cell Responses to Vaccines
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percentage of IFN-c
+ cells in the CD56
dim NK subset [7].
Based on these observations, we propose the following model for
the homeostasis of influenza-specific T-cells during repeated
exposure to influenza infection and vaccination (Figure 2). When
influenza virus or vaccine enters an individual with low levels of
virus-specific memory CD4 T-cells, low levels of baseline reactivity
of CD56
dim NK cells, due to low levels of IL-2 produced by the
CD4 T-cells, favor the antigen-presenting functions of DC and
lead to vigorous virus-specific T-cell responses. In contrast, high
baseline levels of virus-specific memory CD4 T-cells should
enhance NK cell reactivity upon re-exposure to the virus or
vaccine antigens and inhibit DC function by CD56
dim NK cell-
mediated killing of DC. This would lead to limited activation and
expansion of virus-specific T-cells. Alternately or concurrently, the
high levels of NK activity could reverse the function of DC from
activation to tolerization of virus-specific T-cells and render them
anergic, decreasing the production of IFN-c by the virus-specific
T-cell population.
Two of the candidate baseline correlates identified with the 2004
datasetwerenolongersignificantwhen tested withthe2005dataset.
These were age group for CD8 T-cell response and age in years for
HAI response. This could be explained by some differences in the
samples for these two years. All the adult participants, but not the
children, in the 2004 study received the same type of influenza
vaccine in 2003 and 2004 flu seasons; while all adult and child
participants in the 2005 study were randomized to received either
LAIV or TIV. We found both baseline immune parameters as well
as immune responses could be affected by immunization status in
the prior year ([8] and data not shown). In addition, the IFN-c flow
cytometric assay in these two years used different fluA H3N2 strains
matched to the vaccine antigen of each year. These two strains
appear to induce IFN-c production in T-cells and NK cells at
different efficiencies (He et al., unpublished results).
Finally, we recognize that strengths of association are modest at
best between identified baseline correlates and immune responses
identified in the current study. However, it is encouraging that
significant baseline correlates can be identified from our very
limited set of baseline immune parameters after the stringent
screening and testing presented here. In the current study, four out
of the seven immune parameters examined with the 2004 sample
pertain to IFN-c production, which may not be the best
parameter, and definitely not the only parameter, for character-
izing the highly diversified functions of lymphocytes. TCR-based
assays for antigen-specific T-cells, such as tetramer staining, may
provide more accurate quantitative measurement for specific T-
cells. Peptide-MHC microarry-based technology offers the ability
to characterize and analyze multiple epitope-specific T-cell
populations during immune responses [51]. Similarly, multicolor
flow cytometry allows simultaneous measurement of multiple
phosphorylated cellular signal molecules [52] as well as multiple
cytokine production [53] in multiple immune cell subsets,
providing a more complete quantitative and qualitative assessment
for the quality of T-cell response that correlate with the immune
response of disease in some models [53]. Together with
development of other high-throughput analysis technologies,
information on the function of immune systems, including many
biomarkers that were not assessed in the current study but may be
critical for immune responses, can be collected at unprecedented
scale. As for statistical methods, variable-selection technologies are
continuing to evolve, in particular with regard to their ‘‘oracle’’
properties, which is their ability to identify true correlates with
immune response. Identification of baseline immune correlates
with immune response will become increasingly reliable as nascent
statistical and bioinformatical tools for data analysis are more
thoroughly tested and become more widely available. This will not
only lead to precise prediction of immune response of infection,
vaccination and treatment, but also reveal the critical underlying
mechanisms for the processes of disease and health.
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